Related Experiment Video
Updated: Aug 5, 2026

Structured Exercise Regimen in Pulmonary Hypertension-Right Ventricular Failure in an Ovine Model
Published on: May 5, 2026
Poverty and Social Deprivation in Patients With Pulmonary Arterial Hypertension-A PHAR Analysis
Roberto J Bernardo1,2,3, Di Lu4, Haley Hedlin4
1Indiana University School of Medicine, Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine Indianapolis Indiana USA.
Abstract:
Poverty and social deprivation have been associated with impaired clinical outcomes and survival in several chronic diseases. The association between poverty and clinical outcomes in patients with pulmonary arterial hypertension (PAH) remains unclear. We aim to determine the association between federal poverty levels with healthcare use and clinical outcomes in PAH. Using the Pulmonary Hypertension Association Registry, we performed a prospective cohort analysis comparing clinical and socioeconomic characteristics in PAH patients above or below federal poverty levels. We studied the association between federal poverty levels and healthcare use patterns and transplant-free survival using a Cox proportional hazards model. A total of 1396 participants were included, 411 (29.4%) under poverty levels. The in-poverty group was mostly non-White and Hispanic, had mainly public health insurance/Medicaid (37.0% vs. 5.5%; absolute standardized difference [ASD] 0.84), lower educational attainment (17.2% vs. 45.6% college graduate or higher; ASD 0.64), lower rates of employment/retirement (27.3% vs. 71.1%; ASD 0.98), higher frequency of methamphetamine exposure (31.5% vs. 9.8%; ASD 0.57), and lower frequency of idiopathic/heritable PAH (36.0% vs. 47.8%; ASD 0.65), than the not in-poverty group. While there were no differences in severity of disease or treatment, the in-poverty group had higher incidence rate ratios of emergency room visits and hospitalizations (IRR 2.19, 95% CI 1.99-2.40, and 1.51, 95% CI 1.36-1.68, respectively). There were no differences in transplant-free survival (p = 0.10). Poverty was not associated with worse survival in patients with PAH but was associated with higher rates of emergency room visits and hospitalizations, suggesting suboptimal disease control despite similar disease severity.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
